The effect of simvastatin and erythropoietin on renal fibrosis in rats with unilateral ureteral obstruction

References

• Seikaly MG, Ho PL, Emmett L, Fine RN, Tejani A. Chronic renal insufficiency in children: the 2001 annual report of the NAPRTCS. Pediatr Nephrol. 2003;18:796–804
   PubMed Web of Science ®Google Scholar
• Bek K, Akman S, Bilge I, et al. Chronic kidney disease in children in Turkey. Pediatr Nephrol. 2009;24(4):797–806
   Google Scholar
• Chevalier RL. Perinatal obstructive nephropathy. Semin Perinatol. 2004;28(2):124–131
   PubMed Web of Science ®Google Scholar
• Chevalier RL, Kim A, Thornhill BA, Wolstenholme JT. Recovery following relief of unilateral ureteral obstruction in the neonatal rat. Kidney Int. 1999;55:793–807
   Google Scholar
• Chevalier RL, Thornhill BA, Chang AY. Unilateral ureteral obstruction in neonatal rats leads to renal insufficiency in adulthood. Kidney Int. 2000;58:1987–1995
   Google Scholar
• Ito K, Chen J, Chaar ME, et al. Renal damage progresses despite improvement of renal function after relief of unilateral ureteral obstruction in adult rats. Am J Physiol Renal Physiol. 2004;287:1283–1293
   PubMed Web of Science ®Google Scholar
• Chevalier RL, Chung KH, Smith CD, Ficience M, Gomez RA. Renal apoptosis and clusterin following ureteral obstruction: the role of maturation. J Urol. 1996;156:1474–1479
   Web of Science ®Google Scholar
• Boor P, Sebekova K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant. 2007;22(12):3391–3407
   Google Scholar
• Chevalier RL. Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol. 2006;3:157–168
   Google Scholar
• Kuwabara N, Tamada S, Iwia T, et al. Attenuation of renal fibrosis by cucumin in rat obstructive nephropathy. Urology. 2006;67:440–446
   PubMed Web of Science ®Google Scholar
• Tamada S, Asai T, Kuwabara N, et al. Molecular mechanisms and therapeutic strategies of chronic renal injury: the role of nuclear factor kappaB activation in the development of renal fibrosis. J Pharmacol Sci. 2006;100:17–21
   PubMed Web of Science ®Google Scholar
• Chevalier RL, Cachat F. Role of angiotensin II in chronic ureteral obstruction. Contrib Nephrol. 2001;135:250–260
   Web of Science ®Google Scholar
• Miyajima A, Kosaka T, Seta K, Asano T, Umezawa K, Hyakawa M. Novel nuclear factor κB activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. J Urol. 2003;169(4):1559–1563
   PubMed Web of Science ®Google Scholar
• Terada Y, Inoshita S, Nakashima O, et al. Lovastatin inhibits mesangial cell proliferation via p27Kip1. J Am Soc Nephrol. 1998;9:2235–2243
   PubMedGoogle Scholar
• Vesey DA, Cheung C, Pat B, Endre Z, Gobé G, Johnson DW. Erythropoietin protects against ischemic acute renal injury. Nephrol Dial Transplant. 2004;19(2):348–355
   Google Scholar
• Efthimiadou A, Pagonopoulou O, Lambropoulou M, Papadopoulos N, Nikolettos NK. Erythropoietin enhances angiogenesis in an experimental cyclosporine A-induced nephrotoxicity model in the rat. Clin Exp Pharmacol Physiol. 2007;34(9):866–869
   Google Scholar
• Lee SH, Lİ C, Lim SW, et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol. 2005;25(1):64–76
   Google Scholar
• Park SH, Choi MJ, Song IK, et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting tgf-β-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol. 2007;18:1497–1507
   PubMed Web of Science ®Google Scholar
• Banes-Berceli AK, Shaw S, Ma G, et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol. 2006;291:F116–F121
   PubMed Web of Science ®Google Scholar
• Park JK, Muller DN, Mervaala EM, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000;58:1420–1430
   PubMed Web of Science ®Google Scholar
• Li C, Yang CW, Park JH, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol. 2004;286:46–57
   PubMed Web of Science ®Google Scholar
• Baak J, Oort J. A Manual of Morphometry in Diagnostic Pathology. 1st ed. Berlin: Springer-Verlag; 1983
   Google Scholar
• Hatada EN, Krappmann D, Scheidereit C. NF-kB and the innate immune response. Curr Opin Immunol. 2000;12(1):52–58
   Google Scholar
• Kuhad A, Chopra K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci. 2009;84:296–301
   PubMed Web of Science ®Google Scholar
• Nakatani T, Tamada S, Asai T, et al. Role of renin--angiotensin system and nuclear factor-κB in the obstructed kidney of rats with unilateral ureteral obstruction. Jpn J Pharmacol. 2002;90:361–364
   Google Scholar
• Satoh M, Kashihara N, Ymasaki Y, et al. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2001;12:317–325
   PubMed Web of Science ®Google Scholar
• Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:58–63
   PubMed Web of Science ®Google Scholar
• Stancu C, Sima A. Statins mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–387
   PubMed Web of Science ®Google Scholar
• Vieira JM, Mantovani E, Rodrigues LT, et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant. 2005;20:1582–1591
   Google Scholar
• Mondello S, Emanuela Mazzon E, Paola RD, et al. Erythropoietin suppresses peritoneal fibrosis in rat experimental model. Eur J Pharmacol. 2009;604:138–149
   PubMedGoogle Scholar
• Chen G, Shi JX, Hang CH, Xie W, Liu J, Liu X. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett. 2007;425:177–182
   PubMed Web of Science ®Google Scholar
• Xu B, Dong GH, Liu H, Wang YQ, Wu HW, Jing H. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor kappa B. Ann Clin Lab Sci. 2005;35:161–168
   PubMedGoogle Scholar
• Lan HY, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol. 2003;14:1535–1548
   PubMed Web of Science ®Google Scholar
• Srisawat N, Manotham K, Eiam-Ong S, Katavetin P, Praditpornsilpa K, Eiam-Ong S. Erythropoietin and its non-erythropoietic derivative: Do they ameliorate renal tubulointerstitial injury in ureteral obstruction? Int J Urol. 2008;15:1011–1017
   PubMed Web of Science ®Google Scholar
• Strutz F, Zeisberg M, Ziyadeh FN, et al. Role of basic fibroblast growth factor-2 in epithelial--mesenchymal transformation. Kidney Int. 2002;61:1714–1728
   PubMed Web of Science ®Google Scholar